Mayfair Medical

01/01/2022

We end Mayfair Medical 2021 journey with great memories! We will make more awesome memories in 2022 as a family at work too! Having an awesome Boss & a great team lovely makes life fun @ work!!🤍

10/11/2021

04/11/2021

Wishing our patients a joyous Deepavali!
Our clinic is open as per the usual hours to serve your medical needs.

30/10/2021

Back pain? Try this! 🤍

09/08/2021

29/07/2021

[ They are here in Nee Soon East 🎉 ]

Mr. Lim just got his vaccination this morning 🥰 The mobile vaccination teams have arrived in Nee Soon East 😊 They will be here from today until 31 July (9am - 5pm) at Yishun Hearts RC and Yishun Jasmine Residents' Network 👍

Vaccination not only protects yourself but also your loved ones around you and the whole community ❤️ Please do get vaccinated 💪 No appointments needed, just walk in!

19/07/2021

Selamat Hari Raya Haji to our dear Muslim patients! Happy holidays to all! Stay safe and stay healthy.

We remain open today for consultations as usual. :D

09/07/2021

3 Days, 14 Speakers, Online Virtual Summit. Free Registration. Take charge of YOUR fitness and health. Speakers include EIMS (Exercise is Medicine Singapore) Primary Care Physician, to Cardiologists, Orthopaedic Surgeons to Physiotherapists, Nutritionists, Fitness Specialists and Personal Trainers.....

14/06/2021

07/06/2021

Overview

05/05/2021

Headline: Multi-institution four-year liver cancer study recruiting 2000 high-risk patients for participation
The National Cancer Centre of Singapore launched a four-year liver cancer study and plans to recruit 2,000 high-risk patients with hepatocellular carcinoma (HCC) to find out how to more accurately diagnose early HCC and patients at risk for the condition. About 400 to 500 new cases of liver cancer are diagnosed in Singapore each year. Although early diagnosis can increase the chance of cure, only 20% of cases are detected at a stage when cure is possible. There are no confirmed biomarkers for the diagnosis, prediction and prognosis of HCC which would allow for early diagnosis.
Professor Pierce Chow, Principal Investigator of the study and Senior Consultant, Division of Surgery and Surgical Oncology, Singapore General Hospital (SGH) and NCCS pointed out that while patients may be asymptomatic at an early stage, liver cancer can proliferate very quickly.
The ELEGANCE study is recruiting patients between the ages of 50 and 90 at high risk of HCC, who have cirrhosis, hepatitis B or C, non-alcoholic fatty liver, or non-alcoholic steatohepatitis. Prof Chow elaborated on the three goals of the study: to test microRNA in the blood to diagnose HCC, develop an AI algorithm to predict the risk of an individual developing HCC and identify potential therapeutic targets in the metabolome and microbiome which can help prevent HCC and delay the progression of chronic liver disease.

Headline: Multi-institution four-year liver cancer study recruiting 2000 high-risk patients for participation

The National Cancer Centre of Singapore launched a four-year liver cancer study and plans to recruit 2,000 high-risk patients with hepatocellular carcinoma (HCC) to find out how to more accurately diagnose early HCC and patients at risk for the condition. About 400 to 500 new cases of liver cancer are diagnosed in Singapore each year. Although early diagnosis can increase the chance of cure, only 20% of cases are detected at a stage when cure is possible. There are no confirmed biomarkers for the diagnosis, prediction and prognosis of HCC which would allow for early diagnosis.

Professor Pierce Chow, Principal Investigator of the study and Senior Consultant, Division of Surgery and Surgical Oncology, Singapore General Hospital (SGH) and NCCS pointed out that while patients may be asymptomatic at an early stage, liver cancer can proliferate very quickly.

The ELEGANCE study is recruiting patients between the ages of 50 and 90 at high risk of HCC, who have cirrhosis, hepatitis B or C, non-alcoholic fatty liver, or non-alcoholic steatohepatitis. Prof Chow elaborated on the three goals of the study: to test microRNA in the blood to diagnose HCC, develop an AI algorithm to predict the risk of an individual developing HCC and identify potential therapeutic targets in the metabolome and microbiome which can help prevent HCC and delay the progression of chronic liver disease.

Read the article online: www.nccs.com.sg/news/research/multi-institution-four-year-liver-cancer-study-recruiting-2000-high-risk-patients-for-participation